SLC2A1 and neoplasm: This included MVD and GLUT1 expression in tumors with mutated VHL, mTOR phosphorylation in tumors with activating mutations in PI3K/AKT/mTOR pathway genes, H3K36me3 status and mutations in SETD2 and, lastly, the tumor cell proliferation rate and presence of multiple driver gene mutations.